# A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Source: https://onco.cc/trials/nct04965493/  
OnCo record `nct04965493` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pirtobrutinib, Venetoclax and Rituximab in chronic lymphocytic leukaemia, run by Loxo Oncology, Inc., active and no longer recruiting.

## Summary

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) is a phase 3 interventional study registered as NCT04965493 by Loxo Oncology, Inc., with 600 participants enrolled, started 2021-09-20 and due to reach its primary completion in 2026-10. Interventions recorded: Pirtobrutinib, Venetoclax and Rituximab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04965493
- Phase: 3
- Setting: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
- Sponsor: Loxo Oncology, Inc.
- Enrolled: 600

## Sources

- ClinicalTrials.gov NCT04965493: https://clinicaltrials.gov/study/NCT04965493

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Pirtobrutinib](https://onco.cc/drugs/pirtobrutinib/), [Rituximab](https://onco.cc/drugs/rituximab/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct04965493.json